SAN DIEGO – "I think we have a real shot," Axovant Sciences Ltd. CEO David Hung told a rapt audience, speaking about the phase III MINDSET trial in more than 1,300 patients with Alzheimer's disease (AD). Eagerly awaited results with the 5HT6 therapy RVT-101 (intepirdine) are due in September, and hopes are that the positive phase II data from a 684-patient experiment will be duplicated.